Ewing sarcoma is a rare bone and soft tissue cancer that occurs mainly in children and young adults. Treatment typically involves chemotherapy, surgery, and sometimes radiation. About 70% of people with localized disease are cured, but outcomes are worse when the cancer has spread, driving research into new treatments.
What's actually going on in research
Trials are testing targeted drugs that attack specific vulnerabilities in Ewing sarcoma cells, including IGF-1R inhibitors and PARP inhibitors. Immunotherapy approaches are being studied to help the immune system recognize these tumors. Researchers are also testing combinations that might improve chemotherapy response and studying ways to treat or prevent metastatic disease.
Targeted therapy combinations
Drugs targeting IGF-1R and other pathways specific to Ewing sarcoma are being tested alongside chemotherapy. Early trials suggest some combinations may help shrink tumors that don't respond well to standard treatment.
Immunotherapy approaches
Ewing sarcoma cells often hide from the immune system, making them difficult to treat with immunotherapy. Trials are testing CAR T-cell therapy, vaccines, and drugs that expose tumor cells to immune attack.
Maintenance therapy
Studies are testing whether ongoing treatment after initial therapy can prevent relapse. This includes targeted drugs and immune-based approaches given over months or years.
What to know before you search
Eligibility typically depends on whether the cancer is newly diagnosed or relapsed, disease location and extent, prior treatments received, and age.
What types of trials are currently open
- Upfront treatment trials — Testing new drug combinations added to standard chemotherapy for newly diagnosed Ewing sarcoma, aiming to improve cure rates.
- Relapsed disease trials — Testing targeted drugs, immunotherapy, or new chemotherapy combinations for Ewing sarcoma that has returned after initial treatment.
- Maintenance trials — Testing whether treatment given after completion of standard therapy can prevent the cancer from coming back.
- Surgery and radiation studies — Studies comparing different surgical approaches or radiation techniques to preserve function while controlling the tumor.
- Biomarker studies — Research tracking tumor characteristics to predict which patients will respond to specific treatments.
Recently added Ewing Sarcoma trials
Donate blood samples to help monitor Ewing sarcoma treatment progress
This single-center prospective observational study aims to evaluate whether longitudinal changes in serum pro-gastrin-releasing peptide (ProGRP) reflect treatment response in patients with newly diagnosed Ewing sarcoma. Serum ProGRP levels will be measured before systemic treatment, during neoadjuvant chemotherapy, before local treatment, and after local treatment. Changes in ProGRP will be compared with radiographic tumor response assessed according to RECIST version 1.1. The study will also explore the ability of early ProGRP changes to predict objective radiographic response and the association between ProGRP patterns and event-free survival. ProGRP results obtained for research purposes will not be used to guide clinical treatment decisions.
Donate a blood sample to identify sarcoma biomarkers
The study involves blood samples from patients with Ewing's sarcoma to identify circulating biomarkers as a tool for the preclinical validation of innovative therapeutic approaches
Find Ewing Sarcoma trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.